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Case RepoRt
Maternal red blood cell (RBC) alloantibodies can cause hemolytic 
disease of the fetus and newborn (HDFN). Although much is 
described about common antibodies associated with HDFN, 
management of a pregnancy complicated by a maternal rare 
antibody presents several challenges related to assessment of fetal 
anemia risk, availability of blood for transfusion to the mother 
and/or the fetus or newborn if needed, and planning for delivery 
in the case of maternal hemorrhage. Here we report the laboratory 
medicine workup of a patient who presented for obstetrical care 
in the United States in the third trimester and had a rare antibody 
(anti-Inb). Prenatal antibody detection testing demonstrated 
maternal anti-Inb in a 28-year-old woman (gravida 4 para 1021). 
Ultrasound could not rule out fetal anemia. Monocyte monolayer 
assay was performed to assess for the clinical significance of the 
anti-Inb and revealed that the antibody may be capable of causing 
accelerated clearance of antigen-positive RBCs. A local and 
national query revealed that no appropriate units of RBCs were 
available for either the mother or neonate. Given this information, 
serial maternal autologous blood donations were performed, and 
a comprehensive care plan with a multidisciplinary approach for 
delivery, neonatal management, and preparation for hemorrhage 
was developed. Published data and our experience suggest that 
maternal blood donation appears to be a safe and effective way 
to manage mothers who cannot safely use the community blood 
supply. Involvement of obstetric, transfusion medicine, anesthesia, 
and neonatology providers was imperative for a favorable 
outcome. The antibody did not cause clinically significant anemia 
in this infant. Immunohematology 2018;34:7–10.
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Maternal non-D red blood cell (RBC) alloantibodies are 
detected in 1.5–2.5 percent of pregnancies and can cause 
hemolytic disease of the fetus and newborn (HDFN).1 The risk 
of HDFN is not uniform for all antibodies; thus, management 
varies based on identification of the antibody and its strength 
(titer). Because transplacental transfer of antibodies is 
necessary to cause hemolysis of fetal cells, IgG antibodies 
(and not IgM antibodies) are implicated in HDFN. Although 
much is described about common antibodies associated 
with HDFN (anti-K, -c, -E, -Fya, -Fyb, etc.), management of a 
pregnancy complicated by a maternal rare antibody presents 
several challenges related to assessment of fetal anemia risk, 
availability of blood for transfusion to the mother and/or the 
fetus or newborn if needed, and planning for delivery in the 
case of maternal hemorrhage.
Here we report the laboratory medicine workup of a 
patient who presented for obstetrical care in the United States 
in the third trimester and had a rare antibody (anti-Inb). This 
case is unique in that advanced laboratory methodologies 
were used to identify the rare antibody and assess for the 
potential risk of HDFN, given very limited published data. 
We also describe successful serial maternal autologous blood 
donations for banking and multidisciplinary preparation for 
possible hemorrhage at the time of repeat caesarean delivery.
Case Report
A 28-year-old Bangladeshi woman (gravida 4 para 1021) 
at 28 weeks of gestation presented to establish obstetrical care 
with a generalist obstetrician, at which time she was found 
to have a positive antibody detection test. She had previously 
delivered a full-term infant via primary caesarean delivery in 
Bangladesh due to fetal distress negating a vaginal delivery; 
no complications were noted. Her subsequent pregnancies 
included an early first-trimester miscarriage and an ectopic 
pregnancy treated with methotrexate. She had the same 
partner for all pregnancies and denied a history of transfusion. 
Prenatal care occurred in Bangladesh until 28 weeks of 
gestation, and records (including laboratory evaluations) were 
not available for review.
Immunohematologic Evaluation and Results
At her first obstetrical visit in the United States, her blood 
type was found to be group A, D+. The antibody detection test 
was positive with all screening cells (Immucor, Norcross, GA) 
at the antihuman globulin phase of testing (Anti-IgG; Ortho 
Clinical Diagnostics, Raritan, NJ). An antibody identification 
panel was performed by tube indirect antiglobulin test (IAT) 
using reagent panel RBCs (Immucor), ficin-treated RBCs 
(Immucor) as well as dithiothreitol (DTT)-treated (Sigma, 
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St. Louis, MO) reagent RBCs. The patient’s plasma was found 
to react with all reagent panel RBCs tested except those that 
were treated with ficin or DTT. The patient’s plasma was 
negative with her own RBCs (autocontrol), and the direct 
antiglobulin test (DAT) was negative using polyspecific 
AHG (Anti-IgG–C3b,C3d; Immucor). All alloantibodies to 
common RBC antigens were excluded using the ficin- and 
DTT-treated panel RBCs. To confirm the possibility of an 
antibody against a high-prevalence antigen, the laboratory 
verified the patient’s ethnicity to be of Southeast Asian 
descent. Knowing the serologic characteristics of the antibody 
and ethnic background of the patient, preliminary deduction 
of the antibody was thought to be anti-Inb, an antibody to a 
high-prevalence antigen. The patient’s plasma was further 
tested with two examples of rare reagent In(b–) RBCs and 
was found to be nonreactive. Typing the patient’s RBCs for Inb 
was not performed because reagent anti-Inb was not available. 
Because of this reagent unavailability, the specimen was sent 
to another reference laboratory to confirm the presence of anti-
Inb. Eventually, the patient’s RBCs were found to be In(b–) 
with three examples of anti-Inb unlicensed reagents. The titer 
(saline tube-IAT) of the anti-Inb was found to be 4.
To prepare for the possibility of hemorrhage at delivery and 
potential transfusion needs of the fetus, a national search of 
the American Rare Donor Program managed by the American 
Red Cross was conducted for rare RBCs, but this search 
revealed no available blood donors. Next, maternal autologous 
blood donations were performed to bank blood for delivery 
with a planned repeat caesarean. To perform autologous blood 
collection, the threshold for blood donation had to be lowered 
after agreement of the transfusion and obstetrical physicians. 
In addition, careful assessment for underlying anemia was 
undertaken, and the patient was given intravenous and oral 
iron supplementation to prepare for surgery.
The patient was subsequently referred to the maternal–
fetal medicine clinic for consultation at 34 weeks and 6 days 
of gestation to assess the risk of fetal anemia. Ultrasound 
evaluation revealed a singleton fetus with concordant biometry, 
normal amniotic fluid volume, an estimated fetal weight of 3297 
g, and no evidence of hydrops. Middle cerebral artery peak 
systolic velocity (MCA PSV) was 78.0 cm/s (1.54 multiples of 
the median [median: 51.1 cm/s]). Repeat maternal titer was 2, 
and an additional weak antibody (anti-P1) was also detected. 
Anti-P1 was only demonstrable with ficin-treated panel RBCs 
and, therefore, not indicated for titration study. A monocyte 
monolayer assay (MMA) was performed using group O In(b+) 
and group A In(b–) RBCs to assess for the clinical significance 
of anti-Inb. The percentages of reactive monocytes using 
In(b+) RBCs with and without fresh complement were 3.2 and 
4.2 percent, respectively (normal range 0–3%). Results greater 
than 3 percent suggest that the antibody may be capable of 
causing accelerated clearance of antigen-positive RBCs. Serial 
prenatal antibody titrations were carried out at 2 weeks apart; 
a significant rise of anti-Inb titer was not observed.
An attempt to confirm fetal anemia via amniotic fluid 
measurement of ΔOD450 was unsuccessful given maternal 
obesity, a large anterior placenta, no accessible fluid pocket, 
and maternal discomfort. Although concern for fetal anemia 
was low, given the limited information known about this 
antibody, delivery was scheduled for 38 weeks of gestation via 
repeat caesarean. At the time of her maternal–fetal medicine 
consultation, the patient was already scheduled to complete 
one autologous blood donation. The patient’s cousin and sister 
also presented for blood typing. Both were noted to be In(b+); 
thus, they were not appropriate candidates for blood donation. 
To consider whether the mother’s In(b–) blood could be used 
for transfusion to the neonate, ABO genotyping was performed 
on a maternal sample; the result was group A homozygous, 
suggesting that the baby would be group A or AB based on 
known ABO inheritance patterns; the blood type of the baby’s 
father was unknown. Neonatal and anesthesia consults were 
obtained, and, given the lack of available blood bank resources 
and a reasonable maternal hematocrit (Hct) of 34% (normal 
range for third trimester pregnancy 30–40%), the patient 
donated another unit of autologous blood to be banked for her 
procedure and to be used for the neonate if necessary. Cell 
salvage was arranged for as well as preparations for possible 
hysterectomy, if necessary.
Recommended Therapy
The patient underwent an uncomplicated repeat caesarean 
delivery at 38 weeks of gestation and delivered a live-born 
male infant weighing 3907 g, with Apgar scores of 7 and 8. 
Cord milking was performed at the time of birth to reduce the 
risk of neonatal anemia. Estimated maternal blood loss from 
delivery was 500 mL. The patient’s Hct fell to 29 percent from 
31 percent preoperatively. The neonatal Hct at birth was 41 
percent and improved to 46 percent (normal range 42–65%) 
at discharge, without transfusion. Total bilirubin at birth was 
1.8 mg/dL (normal range 0.2–1.3 mg/dL), and reticulocyte 
count was normal at 3.2 percent (normal range 3.0–7.0%). 
The patient and infant were discharged in stable condition on 
postoperative day 3.
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The neonatal blood type was group A, D+. Neonatal RBCs 
were not typed for Inb because there was no anti-Inb antiserum 
available. Furthermore, cord cells have weak expression of Inb. 
DAT and IAT were negative (Table 1).
Discussion
The In antigens are part of the Indian blood group and 
were first described in 1973.2 Ina is a low-prevalence antigen 
present in approximately 0.1 percent of white individuals, 4 
percent of Indian individuals, and approximately 11 percent 
of Middle Eastern populations.3 Conversely, Inb is a high-
prevalence antigen noted in all populations. As such, the 
phenotype In(b–) is quite rare across multiple ethnicities and 
has been noted in approximately 2 of 700 Indian blood donors. 
Two additional high-prevalence antigens, INFI and INJA, 
were added to the Indian blood group system in 2007 after 
their identification. Ina and Inb are encoded by CD44, differ by 
1 base pair, and are carried on the surface glycoprotein CD44. 
IN3 and IN4 are also encoded by CD44.4
Anti-Inb is an IgG antibody based on studies by Joshi5 and 
Ferguson and Gaal.6 In vivo, this antibody has been shown to 
cause a hemolytic reaction with fetal cord blood.6 In limited 
older reports, anti-Inb was not associated with HDFN, although 
maternal titers were low (≤4) in all of these cases.7 A more 
recent Australian case report identified a woman presenting 
with preterm labor and chorioamnionitis at 16 weeks of 
gestation to have anti-Inb on routine blood typing. Similar 
to our case, no In(b–) units were available, necessitating the 
use of intravenous iron and erythropoietin in the setting of 
excessive bleeding at the time of placental removal. Given 
the gestational age in that case, however, no assessment for 
possible HDFN was considered necessary.8
Thus far, anti-Inb has not been implicated in HDFN, 
although case numbers are low and, in some instances, 
this finding may be affected by low antibody titers. It is 
postulated that the risk of HDFN is likely low in these cases 
either because anti-Inb does not readily cross the placenta, or 
because the antibody may be neutralized by CD44 on placental 
macrophages, inhibiting transfer to the fetus.6,7,9 Although the 
literature suggests that HDFN would be unlikely in this case, 
in vivo experiments suggest an ability to cause hemolysis. As 
such, we chose to assume that this fetus may be at risk for 
anemia. In such cases, ΔOD450 testing is useful to evaluate 
fetal anemia; if unable to test for it, little else is available to 
detect clinically significant anemia in the absence of hydrops, 
since measurements of MCA PSV are less reliable at later 
gestational ages.10
Prior reports have implicated anti-Inb in both immediate 
and delayed hemolytic transfusion reactions.5,6 Because of this 
information and because there were no appropriate In(b–) 
blood units available locally or nationally, MMA testing was 
performed to assess the clinical significance of the antibody 
and risk of hemolysis. The percentages of reactive monocytes 
with In(b+) RBCs with fresh complement and without 
fresh complement were 3.2 and 4.2 percent, respectively, 
suggesting the potential for the antibody to clear circulating 
Table 1. Maternal and fetal/neonatal test results and laboratory 
findings
Test Patient’s results Normal reference range
Maternal
Hematology*
Hb 11.1 g/dL 9.5–15.0 g/dL
Hct 34% 30–40%
RBC count 3.95 × 106/mm3 2.71–4.43 × 106/mm3
MCV 86 fL 81–99 fL
WBC count 9.30 × 103/mm3 5.9–16.9 × 103/mm3
Platelet count 195 × 109/L 146–429 × 109/L
Transfusion medicine†
ABO, D Group A, D+












MCA PSV* 78.0 cm/s Median: 51.1 cm/s
Hematology‡
Hct 41% 42–65%
Total bilirubin 1.8 mg/dL 0.2–1.3 mg/dL
Reticulocyte count 3.2% 3.0–7.0%
Transfusion medicine‡
ABO, D A, D+
DAT Negative
IAT Negative
*At 35 weeks of gestation.
†At 28 weeks of gestation.
‡At birth.
Hb = hemoglobin; Hct = hematocrit; RBC = red blood cell; MCV = mean 
corpuscular volume; WBC = white blood cell; DAT = direct antiglobulin test; 
MMA = monocyte monolayer assay; MCA PSV = middle cerebral artery 
peak systolic velocity; IAT = indirect antiglobulin test.
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RBCs. Although the results were slightly over the threshold 
of positive, we felt it was prudent to recommend transfusion 
of ABO- and D-compatible In(b–) RBCs units if the patient 
required transfusion. Of note, MMA testing is not routinely 
recommended for monitoring of HDFN.
In this case, maternal autologous blood donation was 
recommended in anticipation for surgery and for possible 
neonatal use. Autologous blood donation during pregnancy has 
previously been described in the setting of alloimmunization 
and intrauterine transfusion.11,12 In our experience, this 
approach appears to be a safe procedure in these critical 
scenarios. Over the last 10 years, our center has collected and/
or stored RBC units for several women of childbearing potential 
who were not able to use the community blood supply because 
of the presence of an antibody that makes them incompatible 
with most of the population (Table 2). After storage, these 
units are kept frozen until expiration (10 years) in case they 
are needed for use by the patient. Although testing of family 
members to locate appropriate blood donors is recommended 
and should be considered when possible, family donors often 
do not share the same blood type, as was the case with the 
described patient.
A multidisciplinary approach involving transfusion serv-
ices, anesthesia, neonatology, and maternal–fetal medicine 
was essential in this case. Extremely limited RBCs were 
potentially to be shared by both the mother and neonate, and 
thus additional measures (cell salvage, expeditious operating, 
and access to alternative hematologic products [i.e., platelets, 
fresh frozen plasma, cryoprecipitate]) were paramount aspects 
of this case requiring thoughtful planning and feedback from 
the multiple services.
Ultimately, our patient underwent an uncomplicated repeat 
caesarean delivery with minimal blood loss, and her neonate 
did not have anemia. Engagement of our multidisciplinary team 
members resulted in a favorable outcome in this case. Here, we 
have described the management of a maternal rare antibody in 
the setting of extremely limited resources requiring maternal 
autologous blood donations, preparation for possible fetal 
anemia, and preparation for possible maternal hemorrhage.
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Table 2. Maternal blood group types requiring autologous blood 
donation at our center over the past 10 years
Blood Group Type
In(b–)
ENDA–
H– (Bombay)
Para Bombay
